Certara, Inc., together with its subsidiaries, provides technology-enabled services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. The company also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix Hosted, which offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration, which supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform for drug discovery teams and their external collaborators; Certara D360 software, a scientific informatics system for small molecule and biologics discovery research; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and assembles regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.
Valuation Insights | Analysts set price targets from $13 to $18, with Certara trading at 14x estimated 2025 EBITDA, potentially undervalued compared to peers. |
Strategic Positioning | Delve into Certara's strategic initiatives, including its non-animal testing solutions and Cloud platform development, aligning with key industry trends. |
Financial Resilience | Explore Certara's robust financial performance, with Q1 2025 revenue up 10% YoY to $106M, exceeding analyst expectations despite industry challenges. |
Biosimulation Pionee | Certara leads in AI-assisted drug development, offering innovative solutions to streamline pharmaceutical R&D processes and reduce time-to-market for new therapies. |
Metrics to compare | CERT | Sector Sector - Average of metrics from a broad group of related Technology sector companies | Relationship RelationshipCERTPeersSector | |
---|---|---|---|---|
P/E Ratio | −651.4x | −1.3x | −0.5x | |
PEG Ratio | −6.78 | −0.01 | 0.00 | |
Price / Book | 1.6x | 1.0x | 2.6x | |
Price / LTM Sales | 4.3x | 1.6x | 3.2x | |
Upside (Analyst Target) | 44.1% | 8.7% | 43.8% | |
Fair Value Upside | Unlock | 21.9% | 5.1% | Unlock |